Yungjin Pharm. Co., Ltd.
KRX:003520.KS
2365 (KRW) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 234,902.46 | 218,380.987 | 196,067.242 | 208,463.64 | 220,516.292 | 186,408.689 | 195,008.847 | 193,133.853 | 170,203.311 | 167,569.401 | 156,622.683 | 137,688.4 | 112,105.475 | 116,317.39 | 103,376.306 | 110,865.01 | 109,659.792 |
| Cost of Revenue
| 163,963.306 | 153,646.49 | 138,131.208 | 135,000.232 | 140,742.814 | 124,968.306 | 126,165.137 | 121,886.872 | 105,381.544 | 106,390.48 | 99,611.107 | 89,299.275 | 67,381.553 | 64,774.717 | 60,037.964 | 64,944.126 | 70,428.979 |
| Gross Profit
| 70,939.154 | 64,734.498 | 57,936.034 | 73,463.407 | 79,773.479 | 61,440.384 | 68,843.709 | 71,246.981 | 64,821.767 | 61,178.921 | 57,011.576 | 48,389.126 | 44,723.922 | 51,542.673 | 43,338.342 | 45,920.884 | 39,230.813 |
| Gross Profit Ratio
| 0.302 | 0.296 | 0.295 | 0.352 | 0.362 | 0.33 | 0.353 | 0.369 | 0.381 | 0.365 | 0.364 | 0.351 | 0.399 | 0.443 | 0.419 | 0.414 | 0.358 |
| Reseach & Development Expenses
| 11,909.304 | 14,362.836 | 13,260.827 | 15,074.33 | 13,513.249 | 11,988.531 | 13,930.912 | 12,660.814 | 11,787.25 | 9,306.506 | 8,584.355 | 6,620.5 | 4,273.95 | 4,163.797 | 3,433.507 | 3,253.109 | 3,765.762 |
| General & Administrative Expenses
| 2,429.709 | 2,743.133 | 4,035.628 | 4,601.061 | 5,239.725 | 5,143.192 | 5,293.338 | 4,969.09 | 4,466.258 | 4,456.208 | 4,257.171 | 3,949.122 | 3,909.246 | 4,583.143 | 4,798.898 | 6,407.312 | 8,374.962 |
| Selling & Marketing Expenses
| 21,618.81 | 19,689.859 | 19,773.624 | 20,044.994 | 19,676.675 | 16,364.089 | 18,284.511 | 15,976.428 | 13,657.225 | 14,561.201 | 13,880.616 | 14,666.034 | 13,561.263 | 11,890.782 | 19,137.518 | 17,843.568 | 7,674.466 |
| SG&A
| 55,509.809 | 22,432.992 | 23,809.252 | 24,646.055 | 24,916.4 | 21,507.281 | 23,577.849 | 20,945.518 | 18,123.483 | 19,017.409 | 18,137.787 | 18,615.156 | 17,470.509 | 16,473.925 | 23,936.416 | 24,250.88 | 16,049.428 |
| Other Expenses
| -402.647 | 35,301.829 | 34,743.46 | 33,361.569 | 31,361.799 | 250.291 | 722.42 | 299.548 | 91.797 | 467.793 | 7,426.551 | 1,295.383 | 18,745.351 | 28,831.347 | 16,515.599 | -2,057.28 | -2,502.347 |
| Operating Expenses
| 67,821.76 | 72,097.657 | 71,813.539 | 73,081.954 | 69,791.448 | 63,627.73 | 65,814.729 | 65,792.847 | 59,773.927 | 54,202.432 | 50,095.047 | 45,121.372 | 40,489.81 | 49,469.069 | 43,885.522 | 44,258.291 | 46,666.06 |
| Operating Income
| 3,117.394 | -7,363.159 | -13,877.505 | 694.512 | 9,982.031 | -2,187.346 | 3,028.981 | 5,454.134 | 5,047.84 | 6,976.489 | 6,916.53 | 3,267.754 | 4,085.704 | 404.442 | -1,500.972 | 1,662.594 | -7,435.245 |
| Operating Income Ratio
| 0.013 | -0.034 | -0.071 | 0.003 | 0.045 | -0.012 | 0.016 | 0.028 | 0.03 | 0.042 | 0.044 | 0.024 | 0.036 | 0.003 | -0.015 | 0.015 | -0.068 |
| Total Other Income Expenses Net
| -7,035.291 | -15,449.612 | -266.107 | -453.245 | -579.695 | -4,464.196 | -240.589 | -129.956 | -497.002 | -514 | 4,121.591 | -669.602 | -1,040.892 | -3,885.176 | -3,800.797 | -3,337.348 | -7,145.064 |
| Income Before Tax
| -3,917.896 | -22,812.772 | -14,143.612 | 241.267 | 9,402.336 | -6,651.542 | 2,788.392 | 5,324.178 | 4,550.839 | 6,462.489 | 11,038.12 | 2,598.152 | 3,193.22 | -1,811.572 | -4,347.977 | -1,674.755 | -14,580.311 |
| Income Before Tax Ratio
| -0.017 | -0.104 | -0.072 | 0.001 | 0.043 | -0.036 | 0.014 | 0.028 | 0.027 | 0.039 | 0.07 | 0.019 | 0.028 | -0.016 | -0.042 | -0.015 | -0.133 |
| Income Tax Expense
| -42.353 | -851.732 | -2,561.156 | 374.388 | 4,372.412 | -550.602 | 920.672 | 1,121.994 | 1,164.514 | 5,553.397 | -704.21 | 803.924 | 612.391 | 497.094 | -100.859 | 5,058.788 | -2,332.404 |
| Net Income
| -3,875.543 | -21,961.039 | -11,582.456 | -133.121 | 5,029.924 | -6,100.94 | 1,867.72 | 4,202.183 | 3,386.324 | 909.092 | 11,742.33 | 1,794.228 | 2,580.83 | -2,308.666 | -4,347.977 | -6,733.543 | -14,580.311 |
| Net Income Ratio
| -0.016 | -0.101 | -0.059 | -0.001 | 0.023 | -0.033 | 0.01 | 0.022 | 0.02 | 0.005 | 0.075 | 0.013 | 0.023 | -0.02 | -0.042 | -0.061 | -0.133 |
| EPS
| -21.19 | -120.08 | -63.33 | -0.73 | 27.5 | -33.36 | 10 | 24 | 19 | 5 | 66 | 10 | 15 | -16 | -32.84 | -50.6 | -130.49 |
| EPS Diluted
| -21.19 | -120.08 | -63.33 | -0.73 | 27.5 | -33 | 10 | 24 | 19 | 5 | 66 | 10 | 15 | -16 | -32.84 | -50.6 | -130.49 |
| EBITDA
| 11,810.2 | -13,671.677 | -6,410.047 | 8,474.532 | 17,823.18 | 5,249.228 | 10,164.586 | 11,543.144 | 11,073.585 | 12,036.648 | 18,739.26 | 8,601.507 | 8,402.386 | 6,016.96 | 2,793.213 | 6,798.483 | -3,535.912 |
| EBITDA Ratio
| 0.05 | -0.063 | -0.033 | 0.041 | 0.081 | 0.028 | 0.052 | 0.06 | 0.065 | 0.072 | 0.12 | 0.062 | 0.075 | 0.052 | 0.027 | 0.061 | -0.032 |